PCSK9 inhibitors. Recommendations for patient selection

被引：1

作者：

Laufs, U. ^{[1
]}

Custodis, F. ^{[1
]}

Werner, C. ^{[1
]}

机构：

[1] Univ Klinikum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, IMED Geb 41-1, D-66421 Homburg, Germany

来源：

HERZ | 2016年 / 41卷 / 04期

关键词：

Proprotein convertase subtilisin-kexin type 9; Safety; Cholesterol; Risk; Review; CORONARY-HEART-DISEASE; SUBTILISIN/KEXIN TYPE 9; DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; STATIN THERAPY; CARDIOVASCULAR EVENTS; LDL-CHOLESTEROL; REDUCING LIPIDS; AMG; 145;

D O I：

10.1007/s00059-016-4429-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The 2 or 4aEuroweek subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. The therapy is well-tolerated. The safety profile in the published studies is comparable to placebo. Outcome data and information on long-term safety and the influence on cardiovascular events are not yet available but the results of several large trials are expected in 2016-2018. At present (spring 2016) PCSK9 inhibitors represent an option for selected patients with a high cardiovascular risk and high LDL-C despite treatment with the maximum tolerated oral lipid-lowering therapy. This group includes selected patients with familial hypercholesterolemia and high-risk individuals with statin-associated muscle symptoms (SAMS).

引用

页码：296 / 306

页数：11

共 43 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2] Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant [J].

Al-Mashhadi, Rozh H. ;

Sorensen, Charlotte B. ;

Kragh, Peter M. ;

Christoffersen, Christina ;

Mortensen, Martin B. ;

Tolbod, Lars P. ;

Thim, Troels ;

Du, Yutao ;

Li, Juan ;

Liu, Ying ;

Moldt, Brian ;

Schmidt, Mette ;

Vajta, Gabor ;

Larsen, Torben ;

Purup, Stig ;

Bolund, Lars ;

Nielsen, Lars B. ;

Callesen, Henrik ;

Falk, Erling ;

Mikkelsen, Jacob Giehm ;

Bentzon, Jacob F. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (166)

[3] NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol [J].

Benjannet, S ;

Rhainds, D ;

Essalmani, R ;

Mayne, J ;

Wickham, L ;

Jin, WJ ;

Asselin, MC ;

Hamelin, J ;

Varret, M ;

Allard, D ;

Trillard, M ;

Abifadel, M ;

Tebon, A ;

Attie, AD ;

Rader, DJ ;

Boileau, C ;

Brissette, L ;

Chrétien, M ;

Prat, A ;

Seidah, NG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48865-48875

[4] Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy [J].

Berge, KE ;

Ose, L ;

Leren, TP .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) :1094-1100

[5] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].

Cannon, Christopher P. ;

Blazing, Michael A. ;

Giugliano, Robert P. ;

McCagg, Amy ;

White, Jennifer A. ;

Theroux, Pierre ;

Darius, Harald ;

Lewis, Basil S. ;

Ophuis, Ton Oude ;

Jukema, J. Wouter ;

De Ferrari, Gaetano M. ;

Ruzyllo, Witold ;

De Lucca, Paul ;

Im, KyungAh ;

Bohula, Erin A. ;

Reist, Craig ;

Wiviott, Stephen D. ;

Tershakovec, Andrew M. ;

Musliner, Thomas A. ;

Braunwald, Eugene ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397

[6] Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab ( AMG145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy [J].

Cho, Leslie ;

Rocco, Michael ;

Colquhoun, David ;

Sullivan, David ;

Rosenson, Robert S. ;

Dent, Ricardo ;

Xue, Allen ;

Scott, Rob ;

Wasserman, Scott M. ;

Stroes, Erik .

CLINICAL CARDIOLOGY, 2014, 37 (03) :131-139

[7] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease [J].

Cohen, JC ;

Boerwinkle, E ;

Mosley, TH ;

Hobbs, HH .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) :1264-1272

[8] LDL-Cholesterol: From the Hypothesis to Causality [J].

Custodis, Florian ;

Laufs, Ulrich .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (10) :761-U71

[9] Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice [J].

Denis, Maxime ;

Marcinkiewicz, Jadwiga ;

Zaid, Ahmed ;

Gauthier, Dany ;

Poirier, Steve ;

Lazure, Claude ;

Seidah, Nabil G. ;

Prat, Annik .

CIRCULATION, 2012, 125 (07) :894-U173

[10]

DIETSCHY JM, 1993, J LIPID RES, V34, P1637

← 1 2 3 4 5 →